Matthew Korenberg
2017
In 2017, Matthew Korenberg earned a total compensation of $2.2M as Executive Vice President, Finance and Chief Financial Officer at Ligand Pharmaceuticals, a 11% increase compared to previous year.
Compensation breakdown
| Bonus | $30,000 |
|---|---|
| Non-Equity Incentive Plan | $242,063 |
| Option Awards | $768,266 |
| Salary | $403,438 |
| Stock Awards | $736,550 |
| Other | $5,400 |
| Total | $2,185,717 |
Korenberg received $768.3K in option awards, accounting for 35% of the total pay in 2017.
Korenberg also received $30K in bonus, $242.1K in non-equity incentive plan, $403.4K in salary, $736.6K in stock awards and $5.4K in other compensation.
Rankings
In 2017, Matthew Korenberg's compensation ranked 5,090th out of 14,666 executives tracked by ExecPay. In other words, Korenberg earned more than 65.3% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 5,090 out of 14,666 | 65th |
Division Manufacturing | 1,811 out of 5,768 | 69th |
Major group Chemicals And Allied Products | 535 out of 2,074 | 74th |
Industry group Drugs | 412 out of 1,730 | 76th |
Industry Pharmaceutical Preparations | 327 out of 1,329 | 75th |
Source: SEC filing on April 30, 2018.
Korenberg's colleagues
We found three more compensation records of executives who worked with Matthew Korenberg at Ligand Pharmaceuticals in 2017.